Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 7/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17286656 | 0.93 | PLA2G2A (0.40) | SIGMAR1PLA2G2AMTNR1AMTNR1B | |
| SCHEMBL6693579 | 0.90 | FABP4 (0.44) | FABP4FABP3TSPOPLA2G2A | |
| SCHEMBL6688729 | 0.90 | TSPO (0.43) | FABP4TSPOPLA2G2AMEN1KMT2A | |
| SCHEMBL6694139 | 0.89 | TSPO (0.42) | FABP4FABP3TSPOPLA2G2A | |
| SCHEMBL5864512 | 0.86 | TSPO (0.52) | FABP4FABP3TSPOPLA2G2AMTNR1A | |
| SCHEMBL6696662 | 0.83 | PLA2G2A (0.45) | TSPOPLA2G2A | |
| SCHEMBL17286469 | 0.82 | HTT (0.40) | FABP4FABP3 | |
| SCHEMBL6689210 | 0.81 | TSPO (0.43) | FABP4FABP3TSPOPLA2G2A | |
| SCHEMBL8371645 | 0.80 | PLA2G2A (0.47) | PLA2G2A | |
| SCHEMBL420135 | 0.80 | TSPO (0.41) | TSPOMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109231-B2 | Cyclohept[b]indole derivatives | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | KINNICK MICHAEL DEAN (US) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | SPTSSB, CPT1A, TPH2 | FABP4 439/4885FABP3 196/4885TSPO 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.